Agios Pharmaceuticals, Inc. (AGIO) financial statements (2021 and earlier)

Company profile

Business Address 88 SIDNEY STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:671718805568574376467
Cash and cash equivalents12781711031617214
Short-term investments445484515321381245328
Other undisclosed cash, cash equivalents, and short-term investments981532201443259125
Receivables(1)(1)(0) 5813
Inventory, net of allowances, customer advances and progress billings1571    
Inventory1571    
Contract with customer, asset219 
Other undisclosed current assets(69)(122)(192)(123)(19)(47)(121)
Total current assets:637612614445560337360
Noncurrent Assets
Finance lease, right-of-use asset11
Operating lease, right-of-use asset8594
Property, plant and equipment3231242425236
Long-term investments and receivables981532201443259125
Long-term investments981532201443259125
Other noncurrent assets1 01211
Total noncurrent assets:2162792451695983132
TOTAL ASSETS:853891858614619420492
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities87756057493131
Accounts payable27221823171511
Accrued liabilities60534234321614
Employee-related liabilities      6
Deferred revenue 11
Debt07     
Deferred revenue and credits138392236
Other liabilities      0
Other undisclosed current liabilities7 33   (6)
Total current liabilities:94939495885361
Noncurrent Liabilities
Long-term debt and lease obligation98107     
Finance lease, liability01
Operating lease, liability97106
Liabilities, other than long-term debt 5118144172226
Deferred revenue and credits18144172226
Deferred revenue 51
Other undisclosed noncurrent liabilities164 60    
Total noncurrent liabilities:35915777144172226
Total liabilities:4532501712392617568
Stockholders' equity
Stockholders' equity attributable to parent400641688376359345424
Common stock0000000
Additional paid in capital2,2432,1561,7941,175842630591
Accumulated other comprehensive income (loss)00(2)(1)(0)(0)(0)
Accumulated deficit(1,843)(1,516)(1,105)(798)(483)(285)(167)
Total stockholders' equity:400641688376359345424
TOTAL LIABILITIES AND EQUITY:853891858614619420492

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues2031189443705965
Revenue, net43705992
Cost of revenue
(Cost of Goods and Services Sold)
(3)(1)(1) (0)(0)(0)
Gross profit:2001179343705965
Operating expenses(517)(543)(457)(364)(271)(178)(119)
Other undisclosed operating income  1 000
Operating loss:(316)(426)(362)(321)(201)(119)(54)
Nonoperating income
(Investment Income, Nonoperating)
715166310
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(18)    0 
Loss from continuing operations before equity method investments, income taxes:(327)(411)(346)(315)(198)(118)(54)
Other undisclosed loss from continuing operations before income taxes     (0) 
Loss from continuing operations before income taxes:(327)(411)(346)(315)(198)(118)(54)
Income tax benefit      0
Net loss:(327)(411)(346)(315)(198)(118)(54)
Other undisclosed net income attributable to parent0      
Net loss available to common stockholders, diluted:(327)(411)(346)(315)(198)(118)(54)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(327)(411)(346)(315)(198)(118)(54)
Comprehensive loss:(327)(411)(346)(315)(198)(118)(54)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)2(1)(1)0(0)(0)
Comprehensive loss, net of tax, attributable to parent:(327)(409)(347)(316)(198)(118)(54)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: